Showcase

1. Identification of SGLT2 inhibitor Ertugliflozin as a treatment for COVID-19 using computational and experimental paradigm

Shalini Saxena, Kranti Meher, Madhuri Rotella, Subhramanayam Vangala, Satish Chandran, Nikhil Malhotra, Ratnakar Palakodeti, Sreedhara R Voleti, Uday Saxena

bioRxiv 2021.06.18.448921; doi: https://doi.org/10.1101/2021.06.18.448921

2. Tyrosine Kinase Inhibitor Family of Drugs as Prospective Targeted Therapy for COVID-19 Based on In Silico And 3D-Human Vascular Lung Model Studies

Shalini Saxena, Kranti Meher, Madhuri Rotella, Subhramanyam Vangala, Satish Chandran, Nikhil Malhotra, Ratnakar Palakodeti, Sreedhara R Voleti, Uday Saxena

bioRxiv 2021.05.13.443955; doi: https://doi.org/10.1101/2021.05.13.443955

3.  In silico and in vitro Demonstration of Homoharrintonine’s Antagonism of RBD-ACE2 Binding and its Anti-inflammatory and anti-thrombogenic Properties in a 3D human vascular lung model

Shalini Saxena, Kranti Meher, Madhuri Rotella, Subhramanyam Vangala, Satish Chandran, Nikhil Malhotra, Ratnakar Palakodeti, Sreedhara R Voleti, Uday Saxena

bioRxiv 2021.05.02.442384; doi: https://doi.org/10.1101/2021.05.02.442384

4. Provisional Patent: 202041017022